1 hour ago 1

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

Tue, Sep 16, 2025, 8:31 AM 2 min read

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Viatris Inc. is one of them.

Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, continues to expand its presence in both generics and specialty pharmaceuticals. Operating in over 165 countries, the company blends established medicines with innovative therapies, positioning itself as a cost-effective healthcare stock backed by a growing late-stage pipeline.

A key development in 2025 is the FDA approval of Viatris Inc. (NASDAQ:VTRS)’s first generic iron sucrose injection, a version of Venofer, which had annual U.S. sales of approximately $515 million. This approval marks a significant entry into the intravenous iron market and reflects the firm’s focus on high-value complex generics as a cornerstone of its growth strategy.

The corporation has also reported positive late-stage trial results for several pipeline assets, including fast-acting meloxicam for acute pain, the next-generation birth control patch XULANE LO, ophthalmology products for presbyopia, and new indications for EFFEXOR in Japan. For investors tracking cheap healthcare stocks, these successful Phase 3 readouts reinforce the business’s late-stage pipeline and support upcoming product launches and regulatory filings through 2026.

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

Viatris Inc. (NASDAQ:VTRS)’s strategic emphasis on complex generics and specialty products highlights its shift from a primarily generic-focused business to a more innovation-driven company. CEO Scott A. Smith has underscored the resilience of the diversified portfolio and the importance of commercial execution for new launches.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.